Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Geron Corporation (GERN : NSDQ)

• Company Description    Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis. Number of Employees: 72

• Price / Volume Information    Yesterday's Closing Price: $1.41 Daily Weekly Monthly 20 Day Moving Average: 2,210,399 shares Shares Outstanding: 377.45 (millions) Market Capitalization: $532.20 (millions) Beta: 0.99 52 Week High: $2.23 52 Week Low: $0.99 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 0.00% 9.57% 12 Week 35.58% 47.11% Year To Date 15.57% 37.44%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 919 EAST HILLSDALE BOULEVARD SUITE 250 - FOSTER CITY,CA 94404 USA ph: 650-473-7700 fax: 650-473-7750 investor@geron.com http://www.geron.com

• General Corporate Information    Officers John A. Scarlett - President; Chief Executive Officer and Chairman Olivia Bloom - Executive Vice President; Finance; ChiefFinancial Dawn C. Bir - Director Karin Eastham - Director V. Bryan Lawlis - Director Peer Information Geron Corporation (CORR.) Geron Corporation (RSPI) Geron Corporation (CGXP) Geron Corporation (BGEN) Geron Corporation (GTBP) Geron Corporation (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 374163103 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/15/22 Share - Related Items Shares Outstanding: 377.45 Most Recent Split Date: (:1) Beta: 0.99 Market Capitalization: $532.20 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.09 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.37 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/15/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.68 Price/Cash Flow: - Price / Sales: 385.93 EPS Growth vs. Year Ago Period: 0.00% vs. Previous Quarter: 10.00% Sales Growth vs. Year Ago Period: -10.22% vs. Previous Quarter: -88.17% ROE 03/31/22 - -85.84 12/31/21 - -70.87 09/30/21 - -58.33 ROA 03/31/22 - -52.28 12/31/21 - -48.08 09/30/21 - -42.70 Current Ratio 03/31/22 - 3.77 12/31/21 - 4.11 09/30/21 - 4.66 Quick Ratio 03/31/22 - 3.77 12/31/21 - 4.11 09/30/21 - 4.66 Operating Margin 03/31/22 - -8,584.92 12/31/21 - -8,335.39 09/30/21 - -26,769.73 Net Margin 03/31/22 - -8,584.92 12/31/21 - -8,335.39 09/30/21 - -26,769.73 Pre-Tax Margin 03/31/22 - -8,584.92 12/31/21 - -8,335.39 09/30/21 - -26,769.72 Book Value 03/31/22 - 0.26 12/31/21 - 0.39 09/30/21 - 0.47 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.51 12/31/21 - 0.39 09/30/21 - 0.23 Debt-to-Capital 03/31/22 - 33.98 12/31/21 - 28.27 09/30/21 - 18.62

Powered by Zacks Investment Research ©